---
categories: 
- Database
- Release
date: 2021-09-02
title: Database release
---
The following assertions sourced from recent FDA approvals were added to the Molecular Oncology Almanac in this release -

Added entries:
- (FDA) _IDH1_ p.R132C, p.R132H and sensitivity to ivosidenib in acute myeloid leukemia and cholangiocarcinoma.
- (FDA) _IDH1_ somatic variants and sensitivity to ivosidenib in acute myeloid leukemia and cholangiocarcinoma.
- (FDA) _PDGFRA_ p.D842V and sensitivity to avapritinib in gastrointestinal stromal tumors.
- (Preclinical) _KIT_ p.D816V and sensitivity to avapritinib in gastrointestinal stromal tumors.
- (Preclinical) _KIT_ exon 11 and 17 somatic variants and sensitivity to avapritinib in gastrointestinal stromal tumors.
- (Preclinical) _KIT_ somatic variants and sensitivity to avapritinib in mast cell leukemia.
- (Preclinical) _PDGFRA_ p.D842V and sensitivity to avapritinib in gastrointestinal stromal tumors.
- (Preclinical) _PDGFRA_ exon 18 somatic variants and sensitivity to avapritinib in gastrointestinal stromal tumors

Revised entries:
- (Guideline) _PDGFRA_ p.842V and sensitivity to imatinib was revised to not sensitive.